Furthermore, treatment with Src and FAK inhibitors abrogated the promotive effect of RSPO2 on the proliferation and the migration of ovarian cancer cells (Figures 4D, 4E, S4D, and S4E). This evidence concerns the gene RSPO2 and ovarian carcinoma.